gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

V-erb-a erythroblastic leukemia viral oncogene homolog 4

ErbB4, HER4
This gene is a member of the Tyr protein kinase family and the epidermal growth factor receptor subfamily. It encodes a single-pass type I membrane protein with multiple cysteine rich domains, a transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. Mutations in this gene have been associated with cancer. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: erbB-2, EGFR, erbB-3, CAN, Epidermal Growth Factor
Papers using ErbB4 antibodies
A growing family: Adding mutated Erbb4 as a novel cancer target.
Chi Jen-Tsan Ashley, In PLoS ONE, 2009
... To determine whether exon 3 of the ErbB4 gene is skipped in human brain, we used human fetal or adult whole brain Marathon-Ready cDNA library (Clontech, Mountain View, CA), respectively, ...
The PKB/AKT pathway in cancer.
Aiyar Ashok, In PLoS ONE, 2009
... 1∶80 (Novocastra, NCL-CBE-356); HER3 (clone RTJ1), 1∶100 (Novocastra, NCL-c-erbB-3); HER4 (clone sc-283), 1∶500 (Santa Cruz, ErbB-4); Akt1 (clone 2H10), 1∶500 (Cell Signaling, 2967); phospho-Akt (pAkt, Ser473), ...
Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas
Kumar Ujendra et al., In Cancer Cell International, 2003
... ErbB2 (sc-08), ErbB3 (sc-7390), rabbit anti-ErbB1 (sc-03), ErbB2 (sc-284), ErbB3 (sc-285), ErbB4 (sc-283) and goat anti-ErbB4 (sc-283-G) were purchased from Santa Cruz Biotechnology (Santa Cruz, California) ...
Magnitude of binocular vision controlled by islet-2 repression of a genetic program that specifies laterality of retinal axon pathfinding
O'Leary Dennis DM et al., In Neural Development, 2003
... transplantation assays and explant cultures the heart-rescued ErbB4 knockout mice were bred with GFP-expressing transgenic mice [ ...
Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures
Baik Tai-Kyoung et al., In Anatomy & Cell Biology, 2003
... ErbB4 (sc-283, sc-8050) antibody was purchased from Santa Cruz Biotechnology Inc ...
more suppliers
Papers on ErbB4
Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk.
De Keulenaer et al., Antwerp, Belgium. In Am J Physiol Endocrinol Metab, Feb 2016
RhNRG-1 treatment induced systemic activation of ErbB2 and ErbB4 receptors in both heart and kidneys, and prevented LV dilatation, improved LV contractile function and reduced atherosclerotic plaque size.
Co-treatment of wild‑type EGFR head and neck cancer cell lines with afatinib and cisplatin.
Hartmann et al., Würzburg, Germany. In Mol Med Report, Feb 2016
Therefore, other members of the ErbB family, including human epidermal growth factor receptor (HER)2 and HER4, may have important therapeutic roles.
Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells.
Nagano et al., Tokyo, Japan. In Biochem Biophys Res Commun, Feb 2016
ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin.
HER3/ErbB3, an emerging cancer therapeutic target.
An et al., Houston, United States. In Acta Biochim Biophys Sin (shanghai), Jan 2016
HER3 is a member of the HER (EGFR/ErbB) receptor family consisting of four closely related type 1 transmembrane receptors (EGFR, HER2, HER3, and HER4).
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Daub et al., Martinsried, Germany. In Plos One, Dec 2015
While signaling through the EGFR has been extensively studied on the molecular level, signal transduction through ERBB3/ERBB4 heterodimers is less well understood.
Exercise for the heart: signaling pathways.
Li et al., Nanjing, China. In Oncotarget, Sep 2015
The cellular adaptations associated with exercise are due to the activation of several signaling pathways, in particular, the growth factor neuregulin1 (NRG1)-ErbB4-C/EBPβ and insulin-like growth factor (IGF)-1-PI3k-Akt signaling pathways.
Genomic classification of lung cancer: toward a personalized treatment.
El Mezni et al., In Tunis Med, Jun 2015
Upon binding to its ligands, EGFRforms homodimers or heterodimers with other family members(ERBB2, ERBB3 or ERBB4),which inactivate intrinsic receptor tyrosine kinase activity and trigger a phosphorylation cascade of specific tyrosine residues within their cytoplasmicregulatory domains(3).
ErbB4 in Laminated Brain Structures: A Neurodevelopmental Approach to Schizophrenia.
Perez-Garcia, Los Angeles, United States. In Front Cell Neurosci, 2014
I have used the ErbB4(-/-) HER4(heart) KO mice to study the neurodevelopmental insults associated to deficiencies in the NRG1-ErbB4 signaling pathway and their potential implication with brain disorders such as schizophrenia, a chronic psychiatric disease affecting 1% of the population worldwide.
The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis.
Lin et al., Ann Arbor, United States. In Nat Med, 2014
Mechanistically, Nrg4 activates ErbB3 and ErbB4 signaling in hepatocytes and negatively regulates de novo lipogenesis mediated by LXR and SREBP1c in a cell-autonomous manner.
Role of ErbB Receptors in Cancer Cell Migration and Invasion.
Bennasroune et al., Reims, France. In Front Pharmacol, 2014
The ErbB receptor family of RTKs comprises four distinct receptors: the EGFR (also known as ErbB1/HER1), ErbB2 (neu, HER2), ErbB3 (HER3) and ErbB4 (HER4).
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.
Győrffy et al., Budapest, Hungary. In Curr Cancer Drug Targets, 2014
These include HER2 amplification, impaired access to the binding site (p95HER2, Δ16HER-2, MUC4), augmented signaling through other ERBB family receptors (HER1, HER3, HER4) and their ligands, activation of HER2 targets by alternate heterodimers (EphA2, IGF-1R, GDF15, MUC1*), signaling triggered by downstream members (PIK3CA, PTEN, SRC, mTOR), altered expression of cell cycle and apoptotic regulators (CDKs, p27(kip1), Bcl-2), hormone receptor status, resistance to antibody-dependent cellular cytotoxicity (FcγR), and altered miRNA expression signatures.
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.
Liu et al., Shanghai, China. In Nat Genet, 2014
Moreover, ErbB signaling (including EGFR, ERBB2, ERBB3, ERBB4 and their downstream genes) is the most extensively mutated pathway, affecting 36.8% (21/57) of the GBC samples.
Cntnap4 differentially contributes to GABAergic and dopaminergic synaptic transmission.
Fishell et al., In Nature, 2014
Notably, other disease-associated genes such as BDNF and ERBB4 implicate specific interneuron synapses in psychiatric disorders.
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Schuler et al., Boston, United States. In J Clin Oncol, 2013
PURPOSE: The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations.
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Boyer et al., Atlanta, United States. In J Clin Oncol, 2012
PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).
Neuregulin1β1 protects oligodendrocyte progenitor cells from oxygen glucose deprivation injury induced apoptosis via ErbB4-dependent activation of PI3-kinase/Akt.
Sun et al., Shanghai, China. In Brain Res, 2012
Neuregulin1beta1 protected OPCs from OGD induced apoptosis and the possible protective mechanism is linking with ErbB4-dependent activation of PI3-kinase/Akt pathway
Genetic association analysis of ERBB4 polymorphisms with the risk of schizophrenia and SPEM abnormality in a Korean population.
Woo et al., Seoul, South Korea. In Brain Res, 2012
Although statistically not significant, the tendency towards associations between ERBB4 polymorphisms and the risk of schizophrenia and SPEM abnormality in this study from a Korean population would be helpful for further genetic studies in schizophrenia.
A single ligand is sufficient to activate EGFR dimers.
Leahy et al., Baltimore, United States. In Proc Natl Acad Sci U S A, 2012
We report cell-based assays that provide evidence for active, singly ligated dimers of human EGFR and its homolog, ErbB4/HER4.
Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.
Elenius et al., Turku, Finland. In J Biol Chem, 2012
PIAS3 is a novel regulator of ErbB4 receptor tyrosine kinase, controlling its nuclear sequestration and function.
Neuregulin-1 exerts protective effects against neurotoxicities induced by C-terminal fragments of APP via ErbB4 receptor.
Woo et al., Seoul, South Korea. In J Pharmacol Sci, 2011
This effect was blocked by the inhibition of ErbB4, a key NRG1 receptor.
More papers using ErbB4 antibodies
Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitidis
Bourdoulous Sandrine et al., In The Journal of Cell Biology, 2000
... Upstate Biotechnology; antiphosphotyrosine antibody (4G10) was from Meditech; polyclonal antibodies directed against EGFR, ErbB2, ErbB3, ErbB4 were purchased from Santa Cruz Biotechnology, Inc ...
share on facebooktweetadd +1mail to friends